Drug intelligence / Profile preview

BR9003A

Development stage: Preclinical
Lead developer: Boryung
Modality: Small Molecules
Administration: Oral

Overview

BR9003A is an investigational oral pharmaceutical agent studied in clinical trials for its pharmacokinetics and safety profile compared to a related compound, BR9003, in healthy adult subjects. The available data indicate that both BR9003 and BR9003A are being evaluated as separate dosing regimens, with studies comparing once-daily administration of BR9003 to twice-daily administration of BR9003A over six days. The specific mechanism of action, therapeutic indication, and molecular target for BR9003A have not been disclosed in the available sources. The drug is under development by Boryung.

Beyond the preview

Go deeper on BR9003A.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BR9003A.

Explore the full profile